Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the second quarter ended June 30, 2026, on Thursday, August 13, 2026, after the close of U.S.-based financial markets. This disclosure provides investors with an update on the clinical-stage biotechnology company’s progress in developing treatments for autoimmune and chronic inflammatory diseases. The timing of the release allows stakeholders to assess the company’s cash position and pipeline advancements ahead of upcoming regulatory milestones.

Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). The call aims to provide clarity on the company’s financial health and strategic direction during the quarter. Investors are advised to register in advance to access the live audio broadcast and receive dial-in information along with a unique PIN.

The press release and live audio-only webcast of the conference call can be accessed through a link posted on the Home Page and Investors section of the Nektar website at https://ir.nektar.com/ . The web broadcast of the conference call will remain available for replay through September 13, 2026, ensuring that those unable to attend the live session can still review the management commentary and financial details.

Key Dates and Access Information

Pipeline Context

Nektar Therapeutics is focused on addressing underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Its lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel, first-in-class regulatory T cell stimulator. REZPEG is currently being evaluated in a registrational program for atopic dermatitis, with plans for a registrational program in alopecia areata. Additionally, it is being evaluated in one Phase 2 clinical trial for Type 1 diabetes mellitus.

The company’s pipeline also includes preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, designated as NKTR-0165 and NKTR-0166. Furthermore, Nektar is developing a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. These assets represent the core of the company’s long-term growth strategy as it navigates the clinical development landscape.

Contact Information

For investors seeking further details, Vivian Wu can be reached at 628-895-0661 or VWu@nektar.com . Corey Davis, Ph.D., from LifeSci Advisors, is also available at 212-915-2577 or cdavis@lifesciadvisors.com . Media inquiries should be directed to Susan Roberts of LifeSci Communications at 202-779-0929 or sroberts@lifescicomms.com .

Canaccord Genuity analyst Edward Nash has initiated coverage on Nektar Therapeutics with a Buy rating and a price target of $153. The rating reflects confidence in the company's prospects.

Coverage Details

The initiation provides a new outlook for Nektar Therapeutics as the firm establishes its position on the stock.